Considering that the majority of tumors occurred in our series of SOT recipients included non-melanoma skin cancers, our results suggest that monitoring the circulating TERT mRNA levels could identify SOT patients requiring a more frequent clinical and dermatologic follow-up. This evidence concerns the gene TERT and non-melanoma skin carcinoma.